Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

NCR Voyix Corporation (VYX)

NCR Voyix Corporation (VYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
NCR (VYX) Q3 2024 Earnings Call Transcript

VYX earnings call for the period ending September 30, 2024.

VYX : 13.92 (-0.07%)
Why NCR Voyix Stock Was Climbing This Week

The company is transforming into a leaner operation, and one pundit thinks that's a big step in the right direction.

OPY : 62.31 (-0.22%)
VYX : 13.92 (-0.07%)
NCR (VYX) Q2 2024 Earnings Call Transcript

VYX earnings call for the period ending June 30, 2024.

VYX : 13.92 (-0.07%)
NCR Voyix: Q2 Earnings Snapshot

NCR Voyix: Q2 Earnings Snapshot

VYX : 13.92 (-0.07%)
NCR (VYX) Q1 2024 Earnings Call Transcript

VYX earnings call for the period ending March 31, 2024.

VYX : 13.92 (-0.07%)
NCR (VYX) Q4 2023 Earnings Call Transcript

VYX earnings call for the period ending December 31, 2023.

VYX : 13.92 (-0.07%)
NCR Atleos Set to Join S&P SmallCap 600

/PRNewswire/ -- NCR Atleos Corp. (NYSE: NATL) will replace iTeos Therapeutics Inc. (NASD: ITOS) in the S&P SmallCap 600 effective prior to the opening of...

SPGI : 498.25 (+1.31%)
ITOS : 7.35 (-0.94%)
NATL : 33.96 (+5.37%)
NCR : 27.08 (+3.24%)
VYX : 13.92 (-0.07%)

Barchart Exclusives

Why This Dividend Stock Just Scored a Rare Upgrade
Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar